Inhibikase Therapeutics, Inc. Stock Issued During Period, Value, Other
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Inhibikase Therapeutics, Inc. stock issued during period, value, other for the quarter ending 2026-03-31 was $2.90M, a 17.77% increase year-over-year.
- Inhibikase Therapeutics, Inc. stock issued during period, value, other for the quarter ending 2025-06-30 was $150.00, a 100.00% decline year-over-year.
- Inhibikase Therapeutics, Inc. stock issued during period, value, other for the quarter ending 2025-03-31 was $2.46M, a 518.83% increase year-over-year.
- Inhibikase Therapeutics, Inc. stock issued during period, value, other for the quarter ending 2024-09-30 was $24.00, a 99.86% decline year-over-year.
- Inhibikase Therapeutics, Inc. stock issued during period, value, other for fiscal 2025 was $110.08M, a 6.56% increase from fiscal 2024.
- Inhibikase Therapeutics, Inc. stock issued during period, value, other for fiscal 2024 was $103.31M, a 1104.72% increase from fiscal 2023.
- Inhibikase Therapeutics, Inc. stock issued during period, value, other for fiscal 2023 was $8.58M, a 7615.44% increase from fiscal 2022.
- Inhibikase Therapeutics, Inc. stock issued during period, value, other for fiscal 2022 was $111.14K.
| Period end | Stock Issued During Period, Value, Other 3 month | Stock Issued During Period, Value, Other 12 month |
|---|---|---|
| 2026-03-31 | $2.90M 10-Q · filed 2026-08-11 | |
| 2025-12-31 | $110.08M 10-K · filed 2026-03-26 | |
| 2025-06-30 | $150.00 10-Q · filed 2026-08-11 | |
| 2025-03-31 | $2.46M 10-Q · filed 2026-08-11 | |
| 2024-12-31 | $103.31M 10-K · filed 2026-03-26 | |
| 2024-09-30 | $24.00 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $3.25M 10-Q · filed 2025-11-14 | |
| 2024-03-31 | $397.61K 10-Q · filed 2025-11-14 | |
| 2023-12-31 | $8.58M 10-K · filed 2025-03-27 | |
| 2023-09-30 | $17.35K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $95.00 10-Q · filed 2024-11-14 | |
| 2023-03-31 | $8.54M 10-Q · filed 2024-11-14 | |
| 2022-12-31 | $111.14K 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |